Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art
Open Access
- 1 January 2023
- journal article
- review article
- Published by Fedração das Associações de Ginecologia e Obsterícia in RBGO Gynecology & Obstetrics
- Vol. 45 (01), 043-048
- https://doi.org/10.1055/s-0042-1759631
Abstract
Physical and emotional burdens during the journey of infertile people through assisted reproductive technologies are sufficient to justify the efforts in developing patient-friendly treatment strategies. Thus, shorter duration of ovarian stimulation protocols and the need for less injections may improve adherence, prevent mistakes, and reduce financial costs. Therefore, the sustained follicle-stimulating action of corifollitropin alfa may be the most differentiating pharmacokinetic characteristic among available gonadotropins. In this paper, we gather the evidence on its use, aiming to provide the information needed for considering it as a first choice when a patient-friendly strategy is desired. O desgaste físico e emocional durante a jornada de pessoas inférteis pelas tecnologias de reprodução assistida é suficiente para justificar esforços no desenvolvimento de estratégias de tratamento compassivas. Desta forma, a menor duração dos protocolos de estimulação ovariana e a necessidade de menos injeções podem melhorar a adesão, prevenir erros e reduzir custos financeiros. Portanto, a estimulação folicular sustentada da alfacorifolitropina parece ser a característica farmacocinética que melhor a diferencia das gonadotrofinas atualmente disponíveis no mercado. No presente artigo, reunimos evidências sobre seu uso, com o objetivo de fornecer as informações necessárias para considerá-la como primeira escolha quando se deseja uma estratégia amigável ao paciente. Received: 06 April 2022 Accepted: 27 August 2022 Article published online: 06 March 2023 © 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, BrazilKeywords
This publication has 37 references indexed in Scilit:
- Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin αReproductive BioMedicine Online, 2013
- Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trialReproductive Biology and Endocrinology, 2013
- Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatmentHuman Reproduction Update, 2012
- A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormoneFertility and Sterility, 2012
- Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcomeHuman Reproduction, 2012
- Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSHReproductive BioMedicine Online, 2012
- Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicityHuman Reproduction, 2011
- Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trialFertility and Sterility, 2010
- Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight womenReproductive BioMedicine Online, 2010
- A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocolHuman Reproduction, 2009